

CURATIVE BIOTECHNOLOGY, INC.

3801 PGA Blvd Suite 600 Palm Beach Gardens, FL 33410

561-907-8990

<https://curativebiotech.com>

ir@curativebiotech.com

Annual Report

For the period ending December 31, 2025 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

1,072,763,380 as of 12/31/2025 (Current Reporting Period Date or More Recent Date)

1,072,763,380 as of 12/31/2025 (Most Recent Completed Fiscal Year End)

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

⁴ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Curative Biotechnology, Inc., herein referred to as "CUBT" or the "Company."

The company was formerly known as:

Connectyx Technologies Holdings Group, Inc., until April 2021

Storage Innovation Technologies, Inc. until 10-2007

National Boston Medical, Inc. until 5-2004

Fragrance Express, Inc. until 10-1998

Growth Industries, Inc. until 7-1998

Frozen Assets, Inc. until 3-1998

Current State and Date of Incorporation or Registration: Florida, 10/31/2007

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On October 23, 2024, the shareholders of the Corporation approved a written resolution, authorizing the Board, until October 22, 2025, to effect a reverse stock split of not less than 1-for-2 and not more than 1-for- 400 of the Corporation's Common Stock at the discretion of the Board, and reducing the number of authorized shares at the Board's discretion. The reverse was to become effective upon and only upon final approval by FINRA.

On October 14, 2025, the Board of Directors voted to institute a reverse stock split of 1 for 150; and to reduce the authorized shares from One Billion Five Hundred Million to Four Hundred Million shares upon the effectiveness of the reverse. The reverse and the reduction in authorized shares are conditioned upon approval by FINRA of the reverse.

The reverse stock split and the reduction in authorized shares became effective on March 23, 2026.

Address of the issuer's principal executive office:

3801 PGA Blvd Suite 600 Palm Beach Gardens, FL 33410

Address of the issuer's principal place of business:

X Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Equiniti Trust Company, LLC
Phone: +1-919-744-2722
Email: transfer-ID@equiniti.com
Address: 1110 Centre Point Curve, Suite 101
Mendota Heights MN 55120

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

| | |
|--|---|
| Trading symbol: | <u>CUBT</u> |
| Exact title and class of securities outstanding: | <u>Common Stock</u> |
| CUSIP: | <u>23128N108</u> |
| Par or stated value: | <u>\$0.0001</u> |
| Total shares authorized: | <u>1,500,000,000 as of date: 12/31/2025</u> |
| Total shares outstanding: | <u>1,072,763,380 as of date: 12/31/2025</u> |
| Total number of shareholders of record: | <u>231 as of date: 12/31/2025</u> |

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

N/A

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

| | |
|---|---|
| Exact title and class of the security: | <u>Series A Preferred</u> |
| CUSIP (if applicable): | <u>N/A</u> |
| Par or stated value: | <u>\$0.0001</u> |
| Total shares authorized: | <u>1,000,000 as of date: 12/31/2025</u> |
| Total shares outstanding (if applicable): | <u>820,000 as of date: 12/31/2025</u> |
| Total number of shareholders of record: | <u>32 as of date: 12/31/2025</u> |

| | |
|---|---|
| Exact title and class of the security: | <u>Series B Preferred</u> |
| CUSIP (if applicable): | <u>N/A</u> |
| Par or stated value: | <u>\$0.001</u> |
| Total shares authorized: | <u>1,000,000 as of date: 12/31/2025</u> |
| Total shares outstanding (if applicable): | <u>1,000,000 as of date: 12/31/2025</u> |
| Total number of shareholders of record: | <u>38 as of date: 12/31/2025</u> |

| | | |
|---|---------------------------|-------------------------------|
| Exact title and class of the security: | <u>Series C Preferred</u> | |
| CUSIP (if applicable): | N/A | |
| Par or stated value: | <u>\$0.0001</u> | |
| Total shares authorized: | <u>30,000,000</u> | <u>as of date: 12/31/2025</u> |
| Total shares outstanding (if applicable): | <u>24,000,000</u> | <u>as of date: 12/31/2025</u> |
| Total number of shareholders of record: | <u>4</u> | <u>as of date: 12/31/2025</u> |

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

Each holder of record of Common Stock shall have the right to one vote for each share of Common Stock registered in their name on the books of the Corporation on all matters submitted to a vote of shareholders except as the right to exercise such vote may be limited by the provisions of this Third Restated Articles or of any class or series of Preferred Stock established hereunder. The holders of Common Stock shall be entitled to such dividends as may be declared by the Board of Directors from time to time, provided that required dividends, if any, on the Preferred Stock have been paid or provided for. In the event of the liquidation, dissolution, or winding up, whether voluntary or involuntary of the Corporation, the assets and funds of the Corporation available for distribution to shareholders and remaining after the payment to holders of Preferred Stock of the amounts (if any) to which they are entitled, shall be divided and paid to the holders of the Common Stock according to their respective shares.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Series A Preferred Stock

5.1 Designation of Series A Preferred Stock. The designation of the series of preferred stock created hereby shall be "Series A Preferred Stock" (the "**Series A Preferred Stock**") and the number of shares constituting the Series A Preferred Stock shall be One Million shares (1,000,000), with a par value of \$.0001 per share. Such number of shares may from time to time be decreased (but not below the number of shares of Series A Preferred Stock then outstanding) by the Board of Directors (or a duly authorized committee of the Board of Directors) by a certificate executed, acknowledged and filed with the Secretary of State of the State of Florida setting forth a statement that a specified decrease therein has been authorized and directed by a resolution duly adopted by the Board of Directors (or a duly authorized committee of the Board of Directors). In case the number of authorized shares of the Series A Preferred Stock shall be so decreased, the number of shares so specified in the certificate shall resume the status of authorized but unissued shares of preferred stock, undesignated as to series. Shares of Series A Preferred Stock that are

redeemed, purchased or otherwise acquired by the Corporation shall be cancelled and shall revert to authorized but unissued shares of preferred stock, undesignated as to series.

5.2 Dividends on Series A Preferred Stock. The holders of the Series A Preferred Stock shall not be entitled to receive dividends on account of their Series A Preferred Stock.

5.3 Liquidation Preference of Series A Preferred Stock. In the event of any liquidation, dissolution or winding up of the affairs of the Corporation, whether voluntary or otherwise, after payment or provision for payment of the debts and other liabilities of the Corporation, the holders of the Series A Preferred Stock shall be entitled to receive, prior to the holders of any Series A Junior Stock (defined below) and/or Series A Parity Stock (defined below) and prior and in preference to any distribution of the assets or surplus funds of the Corporation to the holders of any other shares of stock of the Corporation by reason of their ownership of such stock, an amount equal to \$1.00 per share with respect to each share of Series A Preferred Stock.

5.4 Conversion of Series A Preferred Stock. The Series A Preferred Stock shall be convertible into shares of Common Stock as follows:

(a) **Conversion Price.** The Conversion price for the Series A Preferred Stock shall be equal to \$0.0025 per share (the "**Conversion Price**").

(b) **Voluntary Conversion.** Each share of Series A Preferred Stock shall be convertible in whole or in part, at the option of the holder thereof at anytime, into that number of fully paid and non-assessable shares of Common Stock as may be purchased for the Conversion Price based on the aggregate purchase price paid for the shares of Series A Preferred Stock (the "**Series A Conversion Right**"). The Series A Conversion Right shall be exercised by a holder submitting written notice to the Corporation informing the Corporation of his/her/its intent to exercise its Series A Conversion Right, specifying the date for such conversion (the "**Series A Conversion Date**") and identifying which shares of Series A Preferred Stock such holder has elected to be converted into Common Stock in accordance with the Series A Conversion Right (the "**Series A Conversion Notice**"). Within ten (10) days of the Corporation's receipt of the Series A Conversion Notice, the Corporation shall be required to provide the respective Series A Preferred Stock holder with written notice setting forth the applicable Series A Conversion Price calculated as of the Series A Conversion Date, including back up calculations therefor, and the number of shares of Common Stock into which the shares of Series A Preferred Stock are being converted. In order to convert the shares of Series A Preferred Stock identified in the Series A Conversion Notice into shares of Common Stock, a holder of Series A Preferred Stock shall be required to surrender at the office of any transfer agent for the Corporation (or to the office of the Corporation if there is no transfer agent), all certificates representing the shares of Series A Preferred Stock elected to be converted, duly endorsed to the Corporation or in blank or marked for cancellation within thirty (30) days of the Series A Conversion Date; *provided that* in the event any holder of Series A Preferred Stock fails to surrender his/her/its certificate(s) representing the shares of Series A Preferred Stock to be converted, the Corporation shall be authorized in all respect to cancel such shares on the books of the Corporation and the transfer agent and to effectuate the conversion of

such shares of Series A Preferred Stock into Common Stock; *provided, further*, that the Corporation shall not be required to deliver the stock certificates representing such shares of Common Stock to their respective holder(s) until such time as the stock certificates representing the Series A Preferred Stock so converted are received by the Corporation or its transfer agent duly endorsed to the Corporation or in blank or marked for cancellation. Shares of the Series A Preferred Stock shall be deemed to have been converted as of the close of business on the Series A Conversion Date, and the person(s) entitled to receive shares of Common Stock issuable upon such conversion shall be treated, for all purposes, as the record holder(s) of such shares of Common Stock at such time.

(c) Mandatory Conversion. In the event that there be a Fundamental Change, the Series A Preferred Stock will automatically convert into that number of shares of Common Stock as may be purchased for the Conversion Price, calculated as of the close of business the day immediately prior to such Fundamental Change, based on the aggregate purchase price paid for the shares of Series A Preferred Stock; *provided* that such Mandatory Conversion shall occur as part of the terms of such consolidation or merger so that any holder of Series A Preferred Stock may thereafter receive in lieu of the Common Stock otherwise issuable to him/her/it upon such Mandatory Conversion of his/her/its Series A Preferred Stock, the same kind and amount of securities as may be distributable upon such consolidation or merger with respect to the Common Stock such holder would have otherwise received.

(d) Additional Provisions Applicable to All Conversions. Any conversion of Series A Preferred Stock into Common Stock pursuant to this Section 6.4 shall be subject to the following additional terms and provisions:

(i) The Corporation shall not be required to issue any fractions of shares of the Common Stock upon conversion of the Series A Preferred Stock into Common Stock.

(ii) In the event that the Corporation shall at any time subdivide or combine in a greater or lesser number of shares the outstanding shares of Common Stock, the Conversion Price of the Series A Preferred Stock shall be adjusted accordingly.

(iii) The holder of Series A Preferred Stock will not receive a distribution in the event that the Corporation shall at any time pay to the holders of its Common Stock a dividend in Common Stock or otherwise makes a distribution on the Common Stock until such a time when the Series A Preferred Stock have been converted into Common Stock.

(iv) As promptly as practicable after any conversion, the Corporation shall issue and deliver at said offices a certificate(s) for the number of full shares of the Common Stock issuable upon any such conversion, to the person(s) entitled to receive the same. The Corporation shall issue the certificate(s) for Common Stock in the name(s) so designated with such legends affixed or restrictions imposed as required by federal, state or jurisdictional securities laws as determined by legal counsel for the Corporation; *provided* that the Corporation is not advised by its counsel that the issuance of such certificate(s) would be in violation of federal, state or jurisdictional securities law.

(v) The issuance of certificates for shares of Common Stock upon conversion of any shares of the Series A Preferred Stock shall be made without charge for any tax in respect of such issuance. However, if any certificate is to be issued in a name other than that of the holder of record of the Series A Preferred Stock so converted, the person or persons requesting, the issuance thereof shall pay to the Corporation the amount of any tax which may be payable in respect of any transfer involved in such issuance, or shall establish to the satisfaction of the Corporation that such tax has been paid or is not due and payable.

5.5 Redemption of Series A Preferred Stock. Subject at all times to the Series A Conversation Right set forth in Section 5.4(b), the issued and outstanding shares of Series A Preferred Stock shall be redeemable, in whole or in part, at the option of the Corporation by resolution of the Board of Directors, from time to time and at any time, commencing any time after the date of issuance of the Series A Preferred Stock as follows:

(a) **Redemption Price.** The redemption price per share of Series A Preferred Stock shall be equal to the greater of: (i) one hundred and twenty five percent (125%) of the purchase price paid for such share or (ii) the book value for such share as determined by an independent auditing firm (the "**Series A Redemption Price**").

(b) **Notice of Redemption.** The Corporation shall give notice of redemption (the "**Series A Redemption Notice**") not less than twenty (20) nor more than sixty (60) calendar days prior to the date fixed for redemption of the Series A Preferred Stock or any part thereof (the "**Series A Redemption Date**"). Such Series A Redemption Notice shall specify the Series A Redemption Date along with the time and place for redemption, and shall be given by mail to each holder of record of shares of Series A Preferred Stock chosen for redemption at the address last shown on the records of the Corporation for such holder or given by such holder to the Corporation for the purpose of notice or, if no such address appears or is given, at the place where the principal executive office of the Corporation is located. Any Series A Redemption Notice which was mailed in the manner herein provided shall be conclusively presumed to have been duly given whether or not the holder received the Series A Redemption Notice.

(c) **Termination of Rights.** Upon the Series A Redemption Date, or upon such earlier date as the Board of Directors shall designate for payment of the Series A Redemption Price (unless the Corporation shall default in the payment of the Series A Redemption Price as set forth in the Series A Redemption Notice), the holders of shares of Series A Preferred Stock selected for redemption to whom notice has been duly given and that have not converted as provided in Section 5.4(b) shall cease to be shareholders with respect to such shares and shall have no interest in or claim against the Corporation by virtue thereof and shall have no other rights with respect to such shares except the right to receive the moneys payable upon such redemption from, the Corporation or otherwise, without interest thereon, upon surrender (and endorsement, if required by the Corporation) of the certificates, and the shares represented thereby shall no longer be deemed to be outstanding.

5.6 Ranking of Series A Preferred Stock. The Corporation may at any time create,

authorize or issue, without the consent of any of the holders of the Series A Preferred Stock, other classes or series of Series A Junior Stock or Series A Parity Stock.

5.7 General Voting Rights of Series A Preferred Stock. Except as otherwise required by law, each holder of record of the Series A Preferred Stock shall be entitled to notice of any and all meetings of the shareholders of the Corporation and shall be entitled to one (1) vote for each full share of Common Stock into which each share of Series A Preferred Stock registered in his/her/its name on the books of the Corporation would be convertible on the record date for any matter submitted to the shareholders of the Corporation for a vote, or, if no such record date is established, at the date such vote is taken or any written consent of shareholders is solicited.

5.8 Certain Voting Rights of Series A Preferred Stock. So long as any share of Series A Preferred Stock remains outstanding, in addition to any other vote or consent of shareholders required by law or by these Articles, the vote or consent of the holders of at least 50.1% of the shares of Series A Preferred Stock at the time outstanding, voting together as a single class, given in person or by proxy, either in writing without a meeting or by vote at any meeting called for the purpose, shall be necessary for effecting or validating:

(a) **Changes Adversely Affecting Series A Preferred Stock.** Any amendment, alteration or repeal of any provision of these Fourth Restated Articles or bylaws of the Corporation that would alter or change the voting powers, preferences or special rights of the Series A Preferred Stock so as to affect it adversely; *provided*, that the amendment of these Fourth Restated Articles so as to authorize or create, or to increase the authorized amount of, any Series A Junior Stock or Series A Parity Stock or any shares of any class or series of any securities convertible into shares of any class or series of Series A Junior Stock or Series A Parity Stock, shall not be deemed to affect adversely the voting powers, preferences or special rights of the Series A Preferred Stock;

(b) **Authorization of Senior Stock.** Any amendment or alteration of these Articles to authorize or create, or increase the authorized amount of, any shares of any class or series or any securities convertible into shares of any class or series of capital stock of the Corporation ranking senior or prior to Series A Preferred Stock in the payment of dividends or in the distribution of assets on any liquidation, dissolution or winding up of the Corporation; or

(c) **Extraordinary Corporate Transactions.**

(i) Consummation of a binding share exchange or reclassification involving the Series A Preferred Stock or a merger or consolidation of the Corporation with another entity, unless in each case (1) shares of Series A Preferred Stock remain outstanding or, in the case of any such merger or consolidation with respect to which the Corporation is not the surviving or resulting entity, are converted into or exchanged for preference securities of the surviving or resulting entity or its ultimate parent, and (2) such shares of Series A Preferred Stock remaining outstanding or such preference securities, as the case may be, have such rights, preferences, privileges and voting powers, taken as a whole, as are not materially less favorable to the holders thereof than the rights, preferences, privileges and voting powers of the Series A Preferred Stock, taken as a whole; *provided*,

however, that any increase in the amount of the authorized or issued Series A Preferred Stock or authorized preferred stock or the creation and issuance, or an increase in the authorized or issued amount, of other Series A Junior Stock and/or Series A Parity Stock of the Corporation will not be deemed to adversely affect the special rights, preferences, privileges or voting powers of the Series A Preferred Stock.

(ii) If an amendment, alteration, repeal, share exchange, reclassification, merger or consolidation described above in clause (i) of this subsection (c) would adversely affect one or more but not all series of preferred stock (including the Series A Preferred Stock for this purpose), then only the series affected and entitled to vote shall vote as a class.

(iii) No vote or consent of the holders of Series A Preferred Stock shall be required pursuant to this subsection (c) if, at or prior to the time when the act with respect to which such vote would otherwise be required, all outstanding shares of Series A Preferred Stock shall have been redeemed or called for redemption upon proper notice and sufficient funds shall have been set aside by the Corporation for the benefit of the holders of Series A Preferred Stock to effect such redemption.

5.9 Amendments to Series A Designation.

(a) General. The designation of the Series A Preferred Stock contained in this Article V may be amended only upon both (i) the affirmative vote of not less than a majority of the holders of the shares of Series A Preferred Stock outstanding at the time such amendment is proposed, and (ii) the affirmative vote of not less than a majority of the directors of the Corporation then holding office and entitled to vote on such amendment.

(b) Changes for Clarification. Without the consent of the holders of the Series A Preferred Stock, so long as such action does not adversely affect the rights, preferences, privileges and voting powers of the Series A Preferred Stock, taken as a whole, the Corporation may amend, alter, supplement or repeal any terms of the Series A Preferred Stock:

(i) to cure any ambiguity, or to cure, correct or supplement any provision contained in these Fourth Restated Articles that may be defective or inconsistent;
or

(ii) to make any provision with respect to matters or questions arising with respect to the Series A Preferred Stock that is not inconsistent with the provisions of these Fourth Restated Articles.

5.10 Certain Definitions. For purposes of these Fourth Restated Articles, the following definitions shall apply:

"Series A Junior Stock" means the Common Stock and any other class or series of stock of the Corporation hereafter authorized over which the Series A Preferred Stock has preference or priority either or both as to the payment of dividends and in the distribution of assets on any liquidation, dissolution or winding up of the Corporation.

"Series A Parity Stock" means the Series B Preferred Stock and any class or series of stock of the Corporation hereafter authorized ranking equally with the Series A Preferred Stock as to both the payment of dividends and the distribution of assets on any liquidation, dissolution or winding up of the Corporation.

Series B Preferred

The holders of the Series B Preferred shall not be entitled to receive dividends.

Liquidation Preference of Series B Preferred Stock. In the event of any liquidation, dissolution or winding up of the affairs of the Corporation, whether voluntary or otherwise, after payment or provision for payment of the debts and other liabilities of the Corporation, the holders of the Series B Preferred Stock shall be entitled to receive, prior to the holders of any Series B Junior Stock (defined below) and/or Series B Parity Stock (defined below) and prior and in preference to any distribution of the assets or surplus funds of the Corporation to the holders of any other shares of stock of the Corporation by reason of their ownership of such stock, an amount equal to \$1.00 per share with respect to each share of Series B Preferred Stock.

Conversion of Series B Preferred Stock. The Series B Preferred Stock shall be convertible into shares of Common Stock as follows:

(a) Conversion Price. The Conversion price for the Series B Preferred Stock shall be equal to \$0.0075 per share (the "**Conversion Price**").

(b) Voluntary Conversion. Each share of Series B Preferred Stock shall be convertible in whole but not in part, at the option of the holder thereof at anytime after the first (1st) anniversary of the date of its issuance, into that number of fully paid and non-assessable shares of Common Stock as may be purchased for the Conversion Price based on the aggregate purchase price paid for the shares of Series B Preferred Stock (the "**Series B Conversion Right**"). The Series B Conversion Right shall be exercised by a holder submitting written notice to the Corporation informing the Corporation of his/her/its intent to exercise its Series B Conversion Right, specifying the date for such conversion (the "**Series B Conversion Date**") and identifying which shares of Series B Preferred Stock such holder has elected to be converted into Common Stock in accordance with the Series B Conversion Right (the "Series B Conversion Notice"). Within ten (10) days of the Corporation's receipt of the Series B Conversion Notice, the Corporation shall be required to provide the respective Series B Preferred Stock holder with written notice setting forth the applicable Series B Conversion Price calculated as of the Series B Conversion Date, including

back up calculations therefor, and the number of shares of Common Stock into which the shares of Series B Preferred Stock are being converted. In order to convert the shares of Series B Preferred Stock identified in the Series B Conversion Notice into shares of Common Stock, a holder of Series B Preferred Stock shall be required to surrender at the office of any transfer agent for the Corporation (or to the office of the Corporation if there is no transfer agent), all certificates representing the shares of Series B Preferred Stock elected to be converted, duly endorsed to the Corporation or in blank or marked for cancellation within thirty (30) days of the Series B Conversion Date; *provided that* in the event any holder of Series B Preferred Stock fails to surrender his/her/its certificate(s) representing the shares of Series B Preferred Stock to be converted, the Corporation shall be authorized in all respect to cancel such shares on the books of the Corporation and the transfer agent and to effectuate the conversion of such shares of Series B Preferred Stock into Common Stock; *provided, further,* that the Corporation shall not be required to deliver the stock certificates representing such shares of Common Stock to their respective holder(s) until such time as the stock certificates representing the Series B Preferred Stock so converted are received by the Corporation or its transfer agent duly endorsed to the Corporation or in blank or marked for cancellation. Shares of the Series B Preferred Stock shall be deemed to have been converted as of the close of business on the Series B Conversion Date, and the person(s) entitled to receive shares of Common Stock issuable upon such conversion shall be treated, for all purposes, as the record holder(s) of such shares of Common Stock at such time.

Mandatory Conversion. In the event that the Corporation shall be consolidated with or merged into any other corporation, the Series B Preferred Stock will automatically convert into that number of shares of Common Stock as may be purchased for the Conversion Price, calculated as of the close of business the day immediately prior to the consummation of such consolidation or merger, based on the aggregate purchase price paid for the shares of Series B Preferred Stock; *provided that* such mandatory conversion shall occur as part of the terms of such consolidation or merger so that any holder of Series B Preferred Stock may thereafter receive in lieu of the Common Stock otherwise issuable to him/her/it upon such mandatory conversion of his/her/its Series B Preferred Stock, the same kind and amount of securities as may be distributable upon such consolidation or merger with respect to the Common Stock such holder would have otherwise received.

Redemption of Series B Preferred Stock. Subject at all times to the Series B Conversion Right set forth in **Section 6.4(b)**, the issued and outstanding shares of Series B Preferred Stock shall be redeemable, in whole or in part, at the option of the Corporation by resolution of the Board of Directors, from time to time and at any time, commencing any time after the date of issuance of the Series B Preferred Stock as follows:

(a) **Redemption Price.** The redemption price per share of Series B Preferred Stock shall be equal to the greater of: (i) one hundred and twenty five percent (125%) of the purchase price paid for such share or (ii) the book value for such share as determined by an independent auditing firm (the "**Series B Redemption Price**").

(b) **Notice of Redemption.** The Corporation shall give notice of redemption (the "**Series B Redemption Notice**") not less than twenty (20) nor more than sixty (60) calendar days prior to the date fixed for redemption of the Series B Preferred Stock or any part thereof (the "**Series B Redemption Date**"). Such Series B Redemption Notice shall specify the Series B Redemption Date along with the time and place for redemption, and shall be given by mail to each holder of record of shares of Series B Preferred Stock chosen for redemption at the address last shown on the records of the Corporation for such holder or given by such holder to the Corporation for the purpose of notice or, if no such address appears or is given, at the place where the principal executive office of the Corporation is located. Any Series B Redemption Notice which was mailed

in the manner herein provided shall be conclusively presumed to have been duly given whether or not the holder received the Series B Redemption Notice.

Termination of Rights. Upon the Series B Redemption Date, or upon such earlier date as the Board of Directors shall designate for payment of the Series B Redemption Price (unless the Corporation shall default in the payment of the Series B Redemption Price as set forth in the Series B Redemption Notice), the holders of shares of Series B Preferred Stock selected for redemption to whom notice has been duly given and that have not converted as provided in **Section 6.3(b)**, shall cease to be shareholders with respect to such shares and shall have no interest in or claim against the Corporation by virtue thereof and shall have no other rights with respect to such shares except the right to receive the moneys payable upon such redemption from, the Corporation or otherwise, without interest thereon, upon surrender (and endorsement, if required by the Corporation) of the certificates, and the shares represented thereby shall no longer be deemed to be outstanding.

General Voting Rights of Series B Preferred Stock. Except as otherwise required by law, each holder of record of the Series B Preferred Stock shall be entitled to notice of any and all meetings of the shareholders of the Corporation and shall be entitled to one (1) vote for each full share of Common Stock into which each share of Series B Preferred Stock registered in his/her/its name on the books of the Corporation would be convertible on the record date for any matter submitted to the shareholders of the Corporation for a vote, or, if no such record date is established, at the date such vote is taken or any written consent of shareholders is solicited

Series C Preferred Stock

The holders of the Series C Preferred shall not be entitled to receive dividends.

Liquidation Preference of Series C Preferred Stock. In the event of any liquidation, dissolution or winding up of the affairs of the Corporation, whether voluntary or otherwise, after payment or provision for payment of the debts and other liabilities of the Corporation, the holders of the Series C Preferred Stock shall be entitled to receive, prior to the holders of any Series C Junior Stock (defined below) and/or Series C Parity Stock (defined below) and prior and in preference to any distribution of the assets or surplus funds of the Corporation to the holders of any other shares of stock of the Corporation by reason of their ownership of such stock, an amount per share equal to the Conversion Rate in **Section 7.04(a)** below with respect to each share of Series C Preferred Stock.

Conversion of Series C Preferred Stock. The Series C Preferred Stock shall be convertible into shares of Common Stock, as follows:

- (c) **Conversion Rate.** All of the issued and outstanding shares of Series C Preferred Stock (the "**Total Series C Shares**") shall collectively be convertible into thirty percent (30%) of the total issued and outstanding shares of Common Stock at the time of such conversion (the "**Conversion Rate**") without any additional consideration by the holders to effectuate the conversion. For the avoidance of doubt, and as an example, in the event of a conversion of Series C Preferred Stock, Series C Preferred Shareholders whose shares have vested will own no more than 30% of all Common Stock post conversion, and the remaining 70% of Common Stock will be held by Common Stock shareholders.

- (d) Voluntary Conversion. Each share of Series C Preferred Stock that has fully vested shall be convertible in whole but not in part, at the option of the holder thereof at any time after the first (1st) anniversary of the date of its vesting, into that number of fully paid and non-assessable shares of Common Stock as may be purchased for the Conversion Price based on the aggregate purchase price paid for the shares of Series C Preferred Stock (the "**Series C Conversion Right**"). The Series C Conversion Right shall be exercised by a holder submitting written notice to the Corporation informing the Corporation of his/her/its intent to exercise its Series C Conversion Right, specifying the date for such conversion (the "**Series C Conversion Date**") and identifying which shares of Series C Preferred Stock such holder has elected to be converted into Common Stock in accordance with the Series C Conversion Right (the "**Series C Conversion Notice**"). Within ten (10) days of the Corporation's receipt of the Series C Conversion Notice, the Corporation shall be required to provide the respective Series C Preferred Stock holder with written notice setting forth the applicable Series C Conversion Price calculated as of the Series C Conversion Date, including back up calculations therefor, and the number of shares of Common Stock into which the shares of Series C Preferred Stock are being converted. In order to convert the shares of Series C Preferred Stock identified in the Series C Conversion Notice into shares of Common Stock, a holder of Series C Preferred Stock shall be required to surrender at the office of any transfer agent for the Corporation (or to the office of the Corporation if there is no transfer agent), all certificates representing the shares of Series C Preferred Stock elected to be converted, duly endorsed to the Corporation or in blank or marked for cancellation within thirty (30) days of the Series C Conversion Date; *provided that* in the event any holder of Series C Preferred Stock fails to surrender his/her/its certificate(s) representing the shares of Series C Preferred Stock to be converted, the Corporation shall be authorized in all respect to cancel such shares on the books of the Corporation and the transfer agent and to effectuate the conversion of such shares of Series C Preferred Stock into Common Stock; *provided, further,* that the Corporation shall not be required to deliver the stock certificates representing such shares of Common Stock to their respective holder(s) until such time as the stock certificates representing the Series C Preferred Stock so converted are received by the Corporation or its transfer agent duly endorsed to the Corporation or in blank or marked for cancellation. Shares of the Series C Preferred Stock shall be deemed to have been converted as of the close of business on the Series C Conversion Date, and the person(s) entitled to receive shares of Common Stock issuable upon such conversion shall be treated, for all purposes, as the record holder(s) of such shares of Common Stock at such time.

Mandatory Conversion. In the event that the Corporation shall be consolidated with or merged into any other corporation, all Series C Preferred Stock shall automatically vest, regardless of any longer vesting schedule set forth in an award document, and will, upon acceleration of vesting, automatically convert into that number of shares of Common Stock as may be issued at the Conversion Rate; *provided that* such mandatory conversion shall occur as part of the terms of such consolidation or merger so that any holder of Series C Preferred Stock may thereafter receive in lieu of the Common Stock otherwise issuable to him/her/it upon such mandatory conversion of his/her/its Series C Preferred Stock, the same kind and amount of securities as may be distributable upon such consolidation or merger with respect to the Common Stock such holder would have otherwise received.

General Voting Rights of Series C Preferred Stock. Except as otherwise required by law, each holder of record of the Series C Preferred Stock shall be entitled to notice of any and all meetings of the shareholders of the Corporation and shall be entitled to ten (10) votes for each full share of Common Stock into which each share of Series C Preferred Stock registered in his/her/its name on the books of the Corporation would be convertible on the record date for any matter submitted to the shareholders of the Corporation for a vote, or, if no such record date is established, at the date such vote is taken or any written consent of shareholders is solicited

3. Describe any other material rights of common or preferred stockholders.

NA

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

NA

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: X (If yes, you must complete the table below)

| Shares Outstanding as of Second Most Recent Fiscal Year End: 12/31/2024 | | | *Right-click the rows below and select "Insert" to add rows as needed. | | | | | | |
|---|---|--|--|---|--|---|---|---|---------------------------------|
| <u>Opening Balance</u> Common: <u>903,263,385</u> Series A Preferred: <u>0</u> Series B Preferred: <u>747,250</u> Series C Preferred: <u>24,000,000</u> | | | | | | | | | |
| Date of Transaction | Transaction type (e.g. new issuance, cancellation, shares returned to treasury) | Number of Shares Issued (or cancelled) | Class of Securities | Value of shares issued (\$/per share) at Issuance | Were the shares issued at a discount to market price at the time of issuance? (Yes/No) | Individual/ Entity Shares were issued to. | Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided | Restricted or Unrestricted as of this filing. | Exemption or Registration Type. |
| <u>02/07/2024</u> | New Issuance | 50,000 | <u>Series B Preferred</u> | 1.00 | <u>N/A</u> | Scott Curran | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>02/08/2024</u> | New Issuance | 50,000 | <u>Series B Preferred</u> | 1.00 | <u>N/A</u> | Tara Barlin | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |

| | | | | | | | | | |
|-------------------|--------------|--------|---------------------------|------|------------|--------------------------------|------------------------|-------------------|----------------|
| <u>02/08/2024</u> | New Issuance | 50,000 | <u>Series B Preferred</u> | 1.00 | <u>N/A</u> | Christina Maclsaac | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>02/08/2024</u> | New Issuance | 25,000 | <u>Series B Preferred</u> | 1.00 | <u>N/A</u> | Melissa and Robert Yee, JTWROS | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>02/08/2024</u> | New Issuance | 25,000 | <u>Series B Preferred</u> | 1.00 | <u>N/A</u> | Christina and Francis Capodica | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>02/08/2024</u> | New Issuance | 2,750 | <u>Series B Preferred</u> | 1.00 | <u>N/A</u> | Rochelle Langer | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>02/09/2024</u> | New Issuance | 25,000 | <u>Series B Preferred</u> | 1.00 | <u>N/A</u> | Veronica G. Mocibob | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>02/12/2024</u> | New Issuance | 25,000 | <u>Series B Preferred</u> | 1.00 | <u>N/A</u> | Brian M. Farrell, Jr. | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/07/2024</u> | New Issuance | 35,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Rochelle Langer | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/07/2024</u> | New Issuance | 50,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Vincent Lanteri | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |

| | | | | | | | | | |
|-------------------|--------------|---------|---------------------------|------|------------|--|------------------------|-------------------|----------------|
| <u>06/07/2024</u> | New Issuance | 20,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Rita Michaelson | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/07/2024</u> | New Issuance | 15,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | GG Capital, LLC (Joseph Gantz) | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/07/2024</u> | New Issuance | 5,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Charles McHenry | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/07/2024</u> | New Issuance | 100,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Crespin Enterprises DBA Collaborate UP (Richard Crespin) | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/07/2024</u> | New Issuance | 25,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Albert and Nickelsha Williams, JTWROS | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 5,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Hancock Western Investments, LLC (David Hancock) | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | John Acito | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 40,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Rita Michaelson | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |

| | | | | | | | | | |
|-------------------|--------------|--------|---------------------------|------|------------|--|------------------------|-------------------|----------------|
| <u>06/17/2024</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | James Bonavita | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Gennadiy Khurgin | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Dina Lemkova-Seryy | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 5,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Tracy Czik Gilvutin | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Viktoria Kats | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Christina Maclsaac | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Tara Berlin | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 25,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Scott Curan | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/17/2024</u> | New Issuance | 25,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Sam Czik Carmel and Hadassa Czik Irrevocable Trust | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |

| | | | | | | | | | |
|-------------------|--------------|------------|---------------------------|-------|------------|---|------------------------|-------------------|-----------------|
| <u>06/28/2024</u> | New Issuance | 50,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Brian M. Farrell, Jr. | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/28/2024</u> | New Issuance | 5,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Melissa and Robert Yee, JTWROS | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/28/2024</u> | New Issuance | 25,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Adam Stern | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/28/2024</u> | New Issuance | 5,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Dean Chenarides | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>06/28/2024</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Josh York | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>10/18/2024</u> | New Issuance | 16,000,000 | <u>Common</u> | .0133 | <u>No</u> | FON Consulting (Len Panzer) | Consultant Fee | <u>Restricted</u> | <u>Rule 144</u> |
| <u>10/16/2024</u> | New Issuance | 50,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Thomas Croft Kocherhans | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>11/14/2024</u> | New Issuance | 50,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Kenneth R. McCarty and Debra McCarty JTWROS | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |

| | | | | | | | | | |
|-------------------|--------------|-----------|---------------------------|------|------------|---|------------------------|-------------------|----------------|
| <u>11/18/2024</u> | New Issuance | 7,500 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Keller Family Trust (Adam Keller) | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>12/16/2024</u> | New Issuance | 25,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | James T. Gordon Revocable Trust (James T. Gordon) | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>01/08/2025</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Anthony Silva | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>01/08/2025</u> | New Issuance | 5,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | John P Narciso | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>01/10/2025</u> | New Issuance | 50,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Despina Farrell | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>01/15/2025</u> | New Issuance | 1,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | David A. Lempert | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>02/04/2025</u> | New Issuance | 35,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Vincent J. Lanteri | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>02/21/2025</u> | New Issuance | 5,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Melissa Seifer | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>02/26/2025</u> | New Issuance | 1,666,666 | <u>Common</u> | .003 | Yes | Louis Paulucci | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |

| | | | | | | | | | |
|-------------------|--------------|------------|---------------------------|-------|------------|---|-------------------------------|-------------------|----------------|
| <u>02/26/2025</u> | New Issuance | 4,666,665 | <u>Common</u> | .003 | Yes | Vincent J. Lanteri | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>03/03/2025</u> | New Issuance | 6,249,998 | <u>Common</u> | .003 | Yes | Nicholas C. Mandorlo | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>03/03/2025</u> | New Issuance | 6,249,998 | <u>Common</u> | .003 | Yes | Anthony Russo, Jr. | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>03/03/2025</u> | New Issuance | 2,500 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Joseph Paul Halsey | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>03/04/2025</u> | New Issuance | 7,999,997 | <u>Common</u> | .003 | Yes | Dr. Tamar Hof-Nir | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>03/19/2025</u> | New Issuance | 8,333,330 | <u>Common</u> | .003 | Yes | Timothy Hartnett | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>03/19/2025</u> | New Issuance | 3,333,332 | <u>Common</u> | .003 | Yes | Holly K. Maschio | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>03/20/2025</u> | New Issuance | 3,333,332 | <u>Common</u> | .003 | Yes | Christopher J. Giorgio | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>03/27/2025</u> | New Issuance | 49,999,980 | <u>Common</u> | .003 | Yes | Marc C. Janis, M.D. | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>04/11/2025</u> | New Issuance | 1,666,666 | <u>Common</u> | .003 | Yes | Jay Gorinson | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>07/15/2025</u> | New Issuance | 33,333,333 | <u>Common</u> | .003 | Yes | Jay More, MD | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>07/22/2025</u> | New Issuance | 40,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Rochelle Langer | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>07/29/2025</u> | New Issuance | 8,333,333 | <u>Common</u> | .003 | Yes | Richard Genetelli | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>08/18/2025</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Damian Donder | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>08/19/2025</u> | New Issuance | 8,333,333 | <u>Common</u> | .003 | Yes | Lalarukh Faiz | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>09/23/2025</u> | Cancellation | 25,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | James T. Gordon Revocable Trust (James T. Gordon) | Conversion to Common | <u>N/A</u> | <u>N/A</u> |
| <u>09/23/2025</u> | New Issuance | 10,000,000 | <u>Common</u> | .0025 | Yes | James T. Gordon Revocable Trust (James T. Gordon) | Conversion Series A Preferred | <u>Restricted</u> | <u>3(a)(9)</u> |
| <u>12/10/2025</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Anthony Russo, Jr. | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| <u>12/10/2025</u> | New Issuance | 10,000 | <u>Series A Preferred</u> | 1.00 | <u>N/A</u> | Nicholas C. Mandorlo | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |

| | | | | | | | | | |
|--|--------------|--------|---------------------------|------|-----|-------------------|------------------------|-------------------|----------------|
| <u>12/23/2025</u> | New Issuance | 25,000 | <u>Series A Preferred</u> | 1.00 | N/A | Richard Genetelli | Subscription Agreement | <u>Restricted</u> | <u>4(a)(2)</u> |
| Shares Outstanding on Date of This Report: <u>Ending Balance</u> Date <u>12/31/2025</u> | | | | | | | | | |
| <u>Ending Balance</u> | | | | | | | | | |
| Common: <u>1,072,763,380</u> | | | | | | | | | |
| Series A Preferred: 820,000 | | | | | | | | | |
| Series B Preferred: 1,000,000 | | | | | | | | | |
| Series C Preferred: 24,000,000 | | | | | | | | | |

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below: N/A

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period

| Date of Note Issuance | Principal Amount at Issuance (\$) | Outstanding Balance (\$) (include accrued interest) | Maturity Date | Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares) | # Shares Converted to Date | # of Potential Shares to be Issued Upon Conversion ⁵ | Name of Noteholder (entities must have individual with voting / investment control disclosed). | Reason for Issuance (e.g., Loan, Services, etc.) |
|-----------------------------------|-----------------------------------|--|----------------------|---|----------------------------|---|--|--|
| 3/3/2022 | 1,142,857 | 3,412,968 | 06/15/2026 | Upon event of default, 70% of lowest closing price for prior 20 trading days. | N/A | N/A | Puritan Partners, LLC (Richard Smithline) | Loan |
| 5/27/2022 | 200,000 | 201,288 | 11/30/2026 | None | N/A | N/A | UC ASSET LP (Jason Cunningham) | Loan |
| 03/14/2023 | 35,000 | 42,756 | 12/31/2026 | None | N/A | N/A | SunMed Advisors, LLC (Barry Ginsberg & Paul Michaels) | Loan |
| Total Outstanding Balance: | | 3,657,012 | Total Shares: | | None | None | | |

Any additional material details, including footnotes to the table are below:

N/A

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three (3) different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform, based on a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease with the goal of being in the clinic in 2026 for a first in human trial of its metformin-based eye drop. The trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.

B. List any subsidiaries, parent company, or affiliated companies.

N/A

C. Describe the issuers' principal products or services.

⁵ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

The Company is focused on developing therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. The Company operates on an outsource model, where its core management group oversees a network of subject matter experts, clinical advisors, manufacturing vendors and regulatory consultants.

5) Issuer’s Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company utilizes Regus office space in Palm Beach Gardens, Florida. The offices have everything taken care of - from the furniture to the high-speed WiFi - and with flexible terms allowing for expansion as needed. The lease term is month to month with a recurring payment of \$129.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer’s securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

| Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity) | Position/Company Affiliation (ex: CEO, 5% Control person) | City and State (Include Country if outside U.S.) | Number of Shares Owned (List common, preferred, warrants and options separately) | Class of Shares Owned | Percentage of Class of Shares Owned (undiluted) |
|---|---|--|--|------------------------------|---|
| Paul M. Michaels | Officer and Director | Boca Raton, FL | 47,377,999 6,000,000 | Common Series C Preferred | 4.42% 25% |

| | | | | | |
|--|-------------------------------------|------------------------|-------------------------|--|----------------|
| Barry A. Ginsberg, O.D. | Consultant Owner of more than 5% | Boca Raton, FL | 97,538,823 6,000,000 | Common Series C Preferred | 9.09% 25% |
| I Richard Garr, J.D. | Officer | Delray Beach, FL | 127,719,282 | Common | 11.91% |
| Ronald W. Bordens, Ph.D. | Officer | Boynton Beach, FL | 250,000 6,000,000 | Common Series C Preferred | <1% 25% |
| Michael J. Grace, Ph.D. | Advisor | Hamilton, NJ | 250,000 6,000,000 | Common Series C Preferred | <1% 25% |
| Cary Sucoff, J.D. | Director | Cold Spring Harbor, NY | -0- | N/A | N/A |
| Lawrence Zaslow | Director | Chappaqua, NY | -0- | N/A | N/A |
| Theresa Heah, M.D., M.B.A. | Director | Hoboken, NJ | -0- | N/A | <u>N/A</u> |
| Rita Michaelson | Owner of more than 5% | New York, NY | 60,000 | Series A Preferred | 7.32% |
| Brian M. Farrell, Jr. | Owner of more than 5% | Clinton, CT | 50,000 | Series A Preferred | 6.10% |
| Despina Farrell | Owner of more than 5% | Clinton, CT | 50,000 | Series A Preferred | 6.10% |
| Crespin Enterprises DBA Collaborate UP (Richard Crespin) | Owner of more than 5% | Falls Church, VA | 100,000 | Series A Preferred | 12.20% |
| Vincent J. Lanteri, M.D. | Owner of more than 5% | Spring Lake, NJ | 80,000 100,000 | Series A Preferred Series B Preferred | 9.76% 10.0% |
| Thomas C. Poss | Director | Guilford, CT | 20,000 | Series B Preferred | 3.16% |
| Thomas Croft Kocherhans | Owner of more than 5% | Orem, UT | 50,000 | Series A Preferred | 6.10% |
| Kenneth R. McCarty and Debra McCarty JTWROS | Owner of more than 5% | Cedar Hill, UT | 50,000 | Series A Preferred | 6.10% |

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

No

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

No

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: Amit Hazan
Firm: Lucosky Brookman, LLP
Address 1: 101 S. Wood Avenue
Address 2: Woodbridge, N.J. 08830
Phone: 732-395-4400
Email: ahazan@lucbro.com

Accountant or Auditor

Name: Michael K. Fish
Firm: Michael K. Fish, CPA PA
Address 1: 7700 N Kendall Dr. #405
Address 2: Miami, FL 33156
Phone: 305-279-8484
Email: mike@mkfishcpa.com

Investor Relations

N/A

All other means of Investor Communication:

Twitter: <https://twitter.com/CurativeBiotech>

Discord: N/A

LinkedIn: <https://www.linkedin.com/company/curative-biotech/>

Facebook: N/A

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Jonathan Leinwand
Firm: Jonathan D. Leinwand, P.A.
Address 1: 18305 Biscayne Blvd., Suite 200
Address 2: Aventura, FL 33180
Phone: 954-903-7856
Email: jonathan@jdlpa.com

Name: Dr. Barry A. Ginsberg
Firm: Barry A Ginsberg, O.D., P.A.
Address 1: 1825 NW Corporate Blvd. Suite 110
Address 2: Boca Raton, FL 33431
Phone: 561-807-8812
Email: bagins@bellsouth.net

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: **Dr. Barry A. Ginsberg**
Title: **Consultant**
Relationship to Issuer: **Consultant**

B. The following financial statements were prepared in accordance with:

IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: **Michael K. Fish**
Title: **Certified Public Accountant**
Relationship to Issuer: **Former Director**

Describe the qualifications of the person or persons who prepared the financial statements.⁶

Mr. Fish has over five years of business experience in the financial sector and had provided accounting and financial consulting services to private companies.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.

⁶ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, I Richard Garr certify that:

1. I have reviewed this Disclosure Statement for Curative Biotechnology Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

03/31/2026 [Date]

/s/ I Richard Garr [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, I Richard Garr certify that:

1. I have reviewed this Disclosure Statement for Curative Biotechnology Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

03/31/2026 [Date]

/s/ I Richard Garr [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

INDEX TO FINANCIAL STATEMENTS

| | |
|--|-----|
| Balance Sheets | F-2 |
| Statements of Operations..... | F-3 |
| Statements of Deficiency in Stockholders' Equity | F-4 |
| Statements of Cash Flows | F-5 |
| Notes to Financial Statements..... | F-6 |

Curative Biotechnology, Inc
Balance Sheets
December 31,

| | 2025 | 2024 |
|--|----------------------------|----------------------------|
| ASSETS | (unaudited) | |
| CURRENT ASSETS | | |
| Cash | \$ 45,043 | \$ 19,534 |
| Prepaid expenses | <u>64,992</u> | <u>164,476</u> |
| Total current assets | <u>110,035</u> | <u>184,010</u> |
| FIXED ASSETS | | |
| Property and equipment | 6,834 | 6,834 |
| Accumulated depreciation | <u>(5,809)</u> | <u>(4,442)</u> |
| Total fixed assets | <u>1,025</u> | <u>2,392</u> |
| OTHER ASSETS | | |
| Deferred offering costs | 690,971 | 655,971 |
| Intangible assets, net | <u>1,307,101</u> | <u>1,348,577</u> |
| Total other assets | <u>1,998,072</u> | <u>2,004,548</u> |
| Total Assets | <u><u>\$ 2,109,132</u></u> | <u><u>\$ 2,190,950</u></u> |
| LIABILITIES AND DEFICIENCY IN STOCKHOLDERS' EQUITY | | |
| CURRENT LIABILITIES | | |
| Accounts payable and accrued liabilities | \$ 4,538,835 | \$ 4,126,588 |
| Short term notes payable and accrued interest, related party | 42,756 | 39,956 |
| Short term note payable and accrued interest | 201,288 | 221,288 |
| Senior secured short term note payable and accrued interest, net of discounts | <u>3,412,968</u> | <u>2,676,496</u> |
| Total current liabilities | <u>8,195,847</u> | <u>7,064,328</u> |
| Total Liabilities | <u>8,195,847</u> | <u>7,064,328</u> |
| Commitments and Contingencies (Note 16) | | |
| DEFICIENCY IN STOCKHOLDERS' EQUITY | | |
| Preferred stock, \$0.0001 par value, authorized 200,000,000 shares: | | |
| Series A, 1,000,000 designated, 826,000 and 647,500 shares issued and outstanding at December 31, 2025 and 2024, respectively | 83 | 65 |
| Series B, 1,000,000 designated, 1,000,000 shares issued and outstanding at December 31, 2025 and 2024, respectively | 100 | 100 |
| Series C, 30,000,000 designated, 24,000,000 shares issued and outstanding at December 31, 2025 and 2024, respectively | 2,400 | 2,400 |
| Common stock, \$0.0001 par value, authorized 400,000,000 shares; 7,151,941 and 6,128,608 shares issued and outstanding at December 31, 2025 and 2024 | 715 | 613 |
| Additional paid-in capital | 38,680,415 | 36,880,370 |
| Accumulated deficit | <u>(44,770,428)</u> | <u>(41,756,926)</u> |
| Total deficiency in stockholders' equity | <u>(6,086,715)</u> | <u>(4,873,378)</u> |
| Total Liabilities and Deficiency in Stockholders' Equity | <u><u>\$ 2,109,132</u></u> | <u><u>\$ 2,190,950</u></u> |

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
Statements of Operations
Year ended December 31,

| | <u>2025</u> | <u>2024</u> |
|--|-----------------------|-----------------------|
| | (Unaudited) | |
| REVENUES | \$ - | \$ - |
| COST OF REVENUES | <u>-</u> | <u>-</u> |
| GROSS MARGIN | - | - |
| OPERATING EXPENSES: | | |
| General and administrative expenses | 1,407,649 | 2,249,718 |
| Research and development expenses | 6,569 | 17,227 |
| Depreciation and amortization | <u>87,843</u> | <u>90,163</u> |
| Total expenses | <u>1,502,061</u> | <u>2,357,108</u> |
| Loss from operations | (1,502,061) | (2,357,108) |
| Other (income) expense: | | |
| Other income | (1,347) | (1,258) |
| Gain on debt forgiveness | (237,596) | - |
| Interest expense | <u>999,955</u> | <u>1,079,979</u> |
| Total other expense, net | <u>761,012</u> | <u>1,078,721</u> |
| Net loss | (2,263,073) | (3,435,829) |
| Series C deemed dividend | <u>(750,431)</u> | <u>(91,200)</u> |
| Net loss to common shareholders | <u>\$ (3,013,504)</u> | <u>\$ (3,527,029)</u> |
| Net loss per basic weighted average common share | <u>\$(0.44)</u> | <u>\$(0.58)</u> |
| Number of weighted average basic and diluted common shares outstanding | <u>6,783,965</u> | <u>6,052,733</u> |

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
Statement of Changes in Deficiency in Stockholders' Equity
(Unaudited)

| | Number of Shares | | | | Par Value | | | | Additional Paid-in Capital | Accumulated Deficit | Total Deficiency in Stockholders' Equity |
|---|------------------|-----------------|------------------|-------------------|---------------|-----------------|-----------------|-----------------|----------------------------------|------------------------|---|
| | Common | Series A Pfd | Series B Pfd | Series C Pfd | Common | Series A Pfd | Series B Pfd | Series C Pfd | | | |
| BALANCE, December 31, 2024 | 6,128,608 | 647,500 | 1,000,000 | 24,000,000 | 613 | 65 | 100 | 2,400 | 36,880,370 | (41,756,926) | (4,873,378) |
| common shares issued for cash | 956,667 | - | - | - | 96 | - | - | - | 430,404 | - | 430,500 |
| Preferred A converted to common | 66,667 | (25,000) | - | - | 7 | (2) | - | - | (5) | - | - |
| Preferred A issued for cash | - | 197,500 | - | - | - | 20 | - | - | 197,480 | - | 197,500 |
| Preferred A issued to settle debt | - | 6,000 | - | - | - | - | - | - | 6,000 | - | 6,000 |
| Warrants issued for services | - | - | - | - | - | - | - | - | 282,402 | - | 282,402 |
| Warrants issued as debt discount | - | - | - | - | - | - | - | - | 74,000 | - | 74,000 |
| Warrants issued to settle debt | - | - | - | - | - | - | - | - | 59,333 | - | 59,333 |
| Series C deemed dividend | - | - | - | - | - | - | - | - | 750,431 | (750,431) | - |
| Net loss | - | - | - | - | - | - | - | - | - | (2,263,073) | (2,263,073) |
| BALANCE, December 31, 2025 | <u>7,151,941</u> | <u>826,000</u> | <u>1,000,000</u> | <u>24,000,000</u> | <u>\$ 716</u> | <u>\$ 83</u> | <u>\$ 100</u> | <u>\$ 2,400</u> | <u>\$38,680,415</u> | <u>\$(44,770,430)</u> | <u>\$(6,086,716)</u> |

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
Statement of Changes in Deficiency in Stockholders' Equity

| | Number of Shares | | | Par Value | | | | Additional Paid-in Capital | Accumulated Deficit | Total Deficiency in Stockholders' Equity | |
|--|------------------|-----------------|------------------|-------------------|---------------|-----------------|-----------------|----------------------------------|------------------------|---|----------------------|
| | Common | Series A Pfd | Series B Pfd | Series C Pfd | Common | Series A Pfd | Series B Pfd | | | | Series C Pfd |
| BALANCE, December 31, 2023 | 6,021,941 | - | 747,250 | 24,000,000 | 602 | - | 75 | 2,400 | 35,084,195 | (38,229,897) | (3,142,625) |
| Warrants issued in connection with debt extension | - | - | - | - | - | - | - | - | 142,857 | - | 142,857 |
| Options for services vesting | - | - | - | - | - | - | - | - | 449,169 | - | 449,169 |
| Common stock issued for services | 106,667 | - | - | - | 11 | - | - | - | 212,789 | - | 212,800 |
| Series B Pfd issued for cash | - | - | 252,750 | - | - | - | 25 | - | 252,725 | - | 252,750 |
| Series A Pfd issued for cash | - | 647,500 | - | - | - | 65 | - | - | 647,435 | - | 647,500 |
| Series C deemed dividend | - | - | - | - | - | - | - | - | 91,200 | (91,200) | - |
| Net loss | - | - | - | - | - | - | - | - | - | (3,435,829) | (3,435,829) |
| BALANCE, December 31, 2024 | <u>6,128,608</u> | <u>647,500</u> | <u>1,000,000</u> | <u>24,000,000</u> | <u>\$ 613</u> | <u>\$ 65</u> | <u>\$ 100</u> | <u>\$ 2,400</u> | <u>\$36,880,370</u> | <u>\$(41,756,926)</u> | <u>\$(4,873,378)</u> |

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
Statements of Cash Flows
Year ended December 31,

| | 2025 | 2023 |
|--|---------------|---------------|
| CASH FLOWS FROM OPERATING ACTIVITIES: | (Unaudited) | |
| Net loss | (\$2,263,073) | (\$3,435,829) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Depreciation and amortization | 87,843 | 92,213 |
| Share based compensation | 282,402 | 976,385 |
| Gain on debt forgiveness | (237,596) | - |
| Amortization of debt discount | 49,333 | 142,857 |
| Accrued interest included in note payable related party | 2,800 | 2,808 |
| Accrued interest included in short-term note payable | 1,288 | (2,901) |
| Accrued interest and penalties included in senior secured convertible note payable | 696,406 | 679,452 |
| Changes in operating assets and liabilities | | |
| Decrease (increase) in prepaid expenses | 99,484 | 79,913 |
| Increase in accounts payable and accrued expenses | 412,247 | 512,769 |
| Net cash used in operating activities | (868,866) | (952,333) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Purchase of intangible assets | - | (15,000) |
| Net cash used in investing activities | - | (15,000) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | |
| Cash received for issuance of Series B preferred stock | - | 252,750 |
| Cash received for issuance of Series A preferred stock | 197,500 | 647,500 |
| Cash received for issuance of common shares | 430,500 | - |
| Increase in deferred offering costs | (35,000) | (85,408) |
| Cash received for short term loan | 79,000 | - |
| Repayment of short term loan | (74,000) | - |
| Cash received from IRS refunds | 296,375 | - |
| Cash received from subscriptions receivable | - | 115,625 |
| Net cash provided by financing activities | 894,375 | 930,467 |
| Net (decrease) increase in cash | 25,509 | (36,866) |
| CASH, beginning of year | 19,534 | 56,400 |
| CASH, end of year | \$ 45,043 | \$ 19,534 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | | |
| Interest paid in cash | \$ 153,690 | \$ 153,690 |
| Income taxes paid in cash | \$ - | \$ - |
| Non-Cash Investing and Financing Activities: | | |
| Common shares issued upon conversion of preferred stock | \$ 7 | \$ - |
| Series C preferred stock deemed dividend | \$ 750,431 | \$ 91,200 |
| Series A preferred stock issued to settle accrued liability | \$ 6,000 | \$ - |
| Insurance premium financing | \$ 70,810 | \$ 126,379 |

The accompanying notes are an integral part of the financial statements

Curative Biotechnology, Inc
Notes to Financial Statements
(Unaudited)

NOTE 1 - NATURE OF OPERATIONS

Curative Biotechnology Inc., (“CUBT” or the “Company”), is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change on November 30, 2020. The Company is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined "Orphan Diseases" with patient populations under 200,000 in the United States. The company leverages management's experience and business relationships with Life Science research institutions as well as Life Science industry members to acquire Life Science candidates that fit within the Company's business model. The Company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

a) Basis of Presentation The accompanying financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).

b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates during 2025 and 2024 include valuation of intangible assets, valuation of stock-based compensation and warrant and option issuance valuations and the valuation of deferred tax assets. Actual results could differ from these estimates.

(c) Cash and equivalents The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents at December 31, 2025 and 2024.

(d) Prepaid expenses From time to time, the Company may prepay expenses either through the transfer of cash, assets or the issuance of securities. Prepaid expenses are generally amortized over the period of benefit.

(e) Property and equipment All property and equipment are recorded at cost and depreciated over their estimated useful life of 5 years, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Depreciation expense was \$1,367 and \$1,367 for the years ended December 31, 2025 and 2024, respectively.

(f) Intangible Assets The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any.

Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. These assets are reviewed for impairment when events or circumstances indicate that the carrying amount of the asset may not be recoverable.

Intangible assets with indefinite useful lives are amortized using a presumed life of 20 years, and are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

(g) Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

(h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments.

FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

(i) Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

(j) Revenue Recognition The Company adopted and will follow Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer”. This revenue recognition standard has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied.

(k) Stock based compensation Stock-based compensation is accounted for based on the requirements of ASC 718 and ASU 2018-07 Compensation - Stock Compensation. ASU 2018-07 simplified the accounting for share-based payments made to non-employees so the accounting for such payments is substantially the same as those made to employees. Under this ASU, share-based awards to non-employees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting, which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees.

Share-Based Payment Topic of ASC 718 requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award or the vesting period, whichever is lesser. The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. For share-based payments to non-employees,” the expense is recognized over the service period of the award.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

(l) Income Taxes Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes. Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities.

(m) Net income (loss) per share Basic income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. At December 31, 2025, the outstanding 2,410,873 warrants and 416,377 options and 2,202,667 and 888,889 and 3,065,038 shares issuable upon conversion of the Series A, Series B and Series C preferred stock, respectively, to common stock are anti-dilutive. At December 31, 2024, the outstanding 434,873 warrants and 416,377 options and 1,726,667 and 888,889 and 2,626,467 shares issuable upon conversion of the Series A, Series B and Series C preferred stock, respectively, to common stock are anti-dilutive.

(n) Recent Accounting Pronouncements In November 2024 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03 Disaggregation of Income Statement Expenses. Although the effective date is for fiscal years beginning after December 31, 2026, the Company has adopted the portions of this ASU that affect its financial statements.

In December 2023 the FASB issued ASU 2023-09 Improvements to Income Tax Disclosures which is effective for fiscal years beginning after December 15, 2025. The Company does not believe that this ASU will have any material effect on its income tax reporting.

(o) Segment reporting The Company operates as a single operating segment company. Per ASC 280 – “*Segment Reporting*”, the Company’s chief operating decision maker has been identified as the President and Chairman of the Board, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similarities in economic characteristics such as nature of services; and procurement processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying balance sheets and statements of operations and notes to statements.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

(o) Segment reporting, continued

The table below provides information about the Company's revenue, significant segment expenses and other segment expenses.

| | Year ended December 31, | |
|----------------------------|--------------------------------|-----------------------|
| | 2025 | 2024 |
| Revenue | \$ - | \$ - |
| Cost of Revenue | - | - |
| Gross profit (loss) | - | - |
| Less segment expenses: | | |
| General and administrative | 1,502,061 | 2,357,108 |
| Operating loss | (1,502,061) | (2,357,108) |
| Plus: | | |
| Interest expense | 999,955 | 1,079,979 |
| Gain on debt forgiveness | (237,596) | - |
| Other income | (1,347) | (1,258) |
| Segment net loss | <u>\$ (2,263,073)</u> | <u>\$ (3,435,829)</u> |

NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company's financial position and operating results raise substantial doubt about the Company's ability to continue as a going concern, as reflected by the net loss of approximately \$2.3 million and cash used in operations of approximately \$0.9 million. The Company also had a working capital deficit and accumulated deficit and deficit in stockholders' equity of approximately \$8.0 million, \$44.8 million and \$6.1 million at December 31, 2025. The ability of the Company to continue as a going concern is dependent upon commencing operations, developing sales and obtaining additional capital and financing. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is currently seeking additional capital to allow it to continue its research and development and related activities.

NOTE 4 - INTANGIBLE ASSETS

During the 4th quarter 2021, the Company acquired the following intangible asset:

(a) MABT Covid-19 license The Company entered into a licensing agreement with Mid-Atlantic BioTherapeutics, Inc., (MABT), to license MABT's COVID-19 vaccine which is composed of a recombinant S1 and S2 protein from SARS-CoV-2 plus an IMT504 adjuvant. The Company issued 12,500,000 shares of common stock valued at \$1,425,000, (\$0.11 per share), to acquire this license.

The stock price was determined at the closing price on the date the agreement was executed and the obligation to issue arose. In April 2022, the Company paid \$39,632 of regulatory and legal costs related to this license. Amortization expense for the years ended December 31, 2025 and 2024 was \$73,282 and \$73,282, respectively, and a net balance of \$1,160,136 and \$1,233,418 at December 31, 2025 and 2024, respectively.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 4 - INTANGIBLE ASSETS, continued

(b) Website In December 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of \$22,500, one-half in cash and one-half in common stock of the Company. The Company began amortizing this cost over 3 years once it was operational. Amortization expense for the years ended December 31, 2025 and 2024 was \$0 and \$1,250, respectively, and a net balance of zero at December 31, 2025 and 2024, respectively.

(c) IMT504 Patent license In October 2020, the Company entered into a license agreement with MidAtlantic BioTherapeutics, Inc., (MABT), to license the development of a pharmaceutical compound known as IMT504, as immunotherapy for late stage symptomatic rabies. The license is for worldwide use. There are certain conditions to the license, principally that the Company raise \$6.5 million to fund the development. There is not a time limit on raising these funds unless the Company utilizes a public offering process, such as Regulation A.

The total cost for this license is 20 million shares of the Company's common stock, issuable in three tranches - 1- 7 million shares upon execution of the license (which have been issued, valued at \$91,000), 2- 6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and 3- 6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504. In March 2022, the Company paid \$30,366 of regulatory and legal costs related to this license. Amortization expense for the years ended December 31, 2025 and 2024 was \$6,200 and \$6,200, respectively, and a net balance of \$91,832 and \$98,032 at December 31, 2025 and 2024, respectively.

(d) National Institute of Health (NIH) Patent license #1 In October 2020, the Company entered into an exclusive 24 month evaluation license of Provisional Patent Application No. 62/199,707, filed July 31, 2015; PCT Application No. PCT/US2016/044777 filed July 29, 2016 and Patent No. 10,548,987 issued February 4, 2020. This license is for the evaluation of and development of an anti-CD56 antibody drug conjugate for the treatment of glioblastoma. Should the Company develop a marketable product, the Company is then required to negotiate a new license with appropriate royalties. This license calls for the payment of a non-creditable non-refundable license issue royalty of \$10,000, paid at issuance and \$5,000 on the one year anniversary and \$10,000 paid in February 2024 for an extension of the license, for a total of \$25,000 to date. In October 2023, the NIH agreed to extend this agreement for an additional 12 months. Amortization expense for the years ended December 31, 2025 and 2024 was \$3,333 and \$2,778, respectively, and a net balance of \$3,889 and \$7,222 at December 31, 2025 and 2024, respectively.

(e) National Institute of Health (NIH) Patent license #2 In January 2021 the Company entered into an NIH exclusive 36 month worldwide license of Provisional Patent Application No. 62/899,899, filed September 13, 2019 and PCT Application No. PCT/US2020/050540 filed September 11, 2020. This license is for the development of ocular metformin formulation for the treatment of retinal degenerative diseases.

This license requires two separate royalty streams of payments: First is a royalty equal to the un-reimbursed patent expenses paid by NIH, with an initial amount of \$8,500 due within 30 days of execution of the license. At the first anniversary of the license NIH will supply a statement of additional un-reimbursed patent expenses paid by NIH during the year, of which the Company is required to pay 50%, with the remaining balance due on the third anniversary. Second is an ongoing royalty schedule: an initial royalty of \$5,000 upon execution of the license, and annually thereafter as the minimum royalty amount. The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of \$45,000. In January 2024, NIH agreed to extend the payment of the \$45,000 fee until April 2, 2025 in exchange for the payment of a \$5,000 fee. Effective March 2025, the NIH agreed to extend this license and the payment of the \$45,000 fee for extension to the end of the patent life, to April 2026, for the payment of a \$2,000 fee. In April 2025, the NIH issued the invoice for the \$45,000 royalty payment. There are three benchmark royalties - \$75,000 upon the initiation of the first Phase 2 Clinical Study; \$300,000 upon the completion of Phase 3 Clinical Study and \$600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of \$100,000 each for the United States, Canada, European Union and Asian region, with an ongoing 3.5% of net sales royalty. Amortization expense for the years ended December 31, 2025 and 2024 was \$3,660 and \$5,285, respectively, and a net balance of \$42,811 and \$1,471 at December 31, 2025 and 2024, respectively.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 4 - INTANGIBLE ASSETS, continued

The Company's aggregate intangible assets were as follows at December 31,

| | <u>2025</u> | <u>2024</u> |
|--------------------------|---------------------|---------------------|
| Total intangible assets | \$ 1,711,946 | \$ 1,666,947 |
| Accumulated Amortization | (404,845) | (318,370) |
| Net intangible assets | <u>\$ 1,307,101</u> | <u>\$ 1,348,577</u> |

The Company's individual intangible assets, net of accumulated amortization, consists of the following at December 31,:

| | <u>Estimated life (years)</u> | <u>2025</u> | <u>2024</u> |
|-----------------------|-------------------------------|---------------------|---------------------|
| Website | 3 | \$ - | \$ - |
| MABT Covid-19 license | 20 | 1,160,135 | 1,233,418 |
| IMT504 Patent license | 20 | 91,832 | 98,032 |
| NIH Patent license #1 | 2 | 3,889 | 7,222 |
| NIH Patent license #2 | 3 | 42,811 | 1,471 |
| Other | 20 | 8,434 | 8,434 |
| Total | | <u>\$ 1,307,101</u> | <u>\$ 1,348,577</u> |

Future amortization is:

| | |
|------------|---------------------|
| 2026 | \$ 82,401 |
| 2027 | 85,735 |
| 2028 | 82,957 |
| 2029 | 82,402 |
| 2030 | 82,402 |
| Thereafter | 891,204 |
| Total | <u>\$ 1,307,101</u> |

Amortization expense was \$86,476 and \$88,796 for the years ended December 31, 2025 and 2024, respectively.

NOTE 5 - RELATED PARTY TRANSACTIONS

From time to time the Company may enter into transactions with related parties.

During the second quarter of 2023, a related party owned by two officers of the Company, extended a loan of \$15,000, which carries an 8% rate of interest and matures on September 2, 2023. In September the maturity date was extended to December 15, 2023. In December 2023, the maturity was extended to February 15, 2024. In January 2024, the lender agreed to extend the maturity date to May 15, 2024. In May 2024, the maturity was extended to September 15, 2024. In September 2024, the maturity date was extended to December 31, 2024. In November 2024, the maturity was extended to February 25, 2025. In February 2025, the maturity

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 5 - RELATED PARTY TRANSACTIONS, continued

was extended to February 25, 2026. In February 2026, the maturity was extended to December 31, 2026. At December 31, 2025, the balance was \$18,271, on the accompanying balance sheet, including accrued interest of \$3,271.

During the first quarter of 2023, a related party owned by two officers of the Company, extended a loan of \$20,000, which carries an 8% rate of interest and matured on June 14, 2023. In June 2023, the maturity of this note was extended to September 14, 2023. In September the maturity date was extended to December 15, 2023. In December 2023, the maturity was extended to February 15, 2024. In January 2024, the lender agreed to extend the maturity date to May 15, 2024. In May 2024, the maturity was extended to September 15, 2024. In September 2024, the maturity date was extended to December 31, 2024. In November 2024, the maturity was extended to February 25, 2025. In February 2025, the maturity was extended to February 25, 2026. In February 2026, the maturity was extended to December 31, 2026. At December 31, 2025, the balance was \$24,484, on the accompanying balance sheet, including accrued interest of \$4,484.

NOTE 6 - NOTES PAYABLE

On May 27, 2022, the Company issued a promissory note in exchange for \$200,000 in cash. This note carries a 12% interest rate, interest payable monthly, and a six month maturity. At maturity, the maturity was extended for an additional six months. On May 27, 2023/ the maturity date was extended to December 16, 2023 and the interest rate was increased to 18%, interest payable monthly. On December 16, 2023, the maturity date was extended to January 31, 2024, upon the payment of \$18,000 of accrued interest. In January 2024, the note was extended to May 31, 2024, upon the payment of a \$6,000 late fee by February 1, 2024, and \$6,250 for accrued interest and a \$250 late fee by February 29, 2024. In May 2024, the note was extended to July 31, 2024, upon the payment of \$12,000 of accrued interest. In August 2024, the Company and the lender agreed to fifth extension of the note and the maturity was reset to September 30, 2024. In November 2024, was extended to November 30, 2025. In November 2025, was extended to November 30, 2026. Upon default, as defined in the note, all amounts become due. The balance was \$221,288 including principal of \$200,000 and accrued interest of \$21,288 at December 31, 2025.

NOTE 7 - SENIOR SECURED NOTE PAYABLE

On March 2, 2022, the Company issued a 12-month Senior Secured Note with a face amount of \$1,142,857, with a stated 12.5% original issue discount (OID). The Note carries a 12.5% interest rate with interest-only payable monthly from April through August 2022. The Company received \$869,972 in cash, net of the OID of \$142,857 and legal and other fees in the amount of \$120,028.

The Note is secured by all the tangible and intangible assets of the Company and is summarized as follows:

| | 2025 | 2024 |
|--------------------------------|--------------------|--------------------|
| Note payable | \$ 1,142,857 | \$ 1,142,857 |
| Accrued interest and penalties | 2,270,111 | 1,533,639 |
| Unamortized discounts | - | - |
| | \$3,412,968 | \$2,676,496 |

Beginning in September 2022, the Company was required to make monthly redemptions at the rate of 110% of one seventh of the original principal amount, (\$179,592), plus interest. It also carries a mandatory prepayment at 125% of the original principal amount, or \$1,428,571, less any redemptions made, plus any unpaid accrued interest upon the completion of a Qualified Offering, as defined or sale of substantially all assets of the Company or a change of control of the Company. In the event that the Company issues or sells additional shares of Common Stock or Common Stock Equivalents in a Qualified Offering at a price per share which multiplied by 75% is less than the Warrant Calculation Price, the number of Warrant Shares issuable upon exercise of this Warrant will increase to be equal to the product obtained by multiplying: (WCP/BP) x (WS) whereby: (WCP) = the Warrant Calculation Price. (BP) = 75% of the price per share sold in the Qualified Offering. (WS) = the number of Warrant Shares that would be issuable upon exercise

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 7 - SENIOR SECURED NOTE PAYABLE, continued

of this Warrant in accordance with the terms of this Warrant immediately prior to the Qualified Offering if such exercise were by means of a cash exercise rather than a cash-less exercise; The term "Warrant Calculation Price" means \$0.05

The Note is convertible at the election of the holder into common stock of the Company upon an event of default, as defined. The conversion price is 70% of the lowest closing price of the Company's common stock for the prior 20 trading days. The lender received five-year warrants to purchase 152,381 shares of common stock of the Company, with an exercise price of \$0.015 per share. The relative fair value of these warrants were recorded as debt discount in the amount of \$531,983 which was amortized over the term of the Note, and was fully amortized as of December 31, 2025. The warrants can be exercised on a cash-less basis if a registration statement for the common shares underlying the warrants is not declared effective by September 2022.

In August 2022, the Company and the lender agreed to the first modification of the Note. In exchange for a one-month extension to begin the principal payments under this Note, the parties agreed to reduce the qualified offering amount from \$10 million to \$7.2 million; modify the payment schedule from seven (7) months to six (6) months. In addition, the lender received 12,698 additional warrants having a fair value of \$58,884, (\$0.03 per share), which were recorded as an additional debt discount and amortized over the remaining life of the Note.

In October 2022, the Company and the lender agreed to the second modification of the Note. The first payment due was delayed from October 2, 2022 to October 17, 2022. In October 2022, the Company and the lender agreed to the third modification of the Note. The first payment due was delayed from October 17, 2022 to November 2, 2022. The lender received 12,698 additional warrants having a fair value of \$36,053, which were recorded as an additional debt discount and amortized over the remaining life of the Note.

In November 2022, the Company and the lender agreed to the fourth modification of the Note. The first payment due was delayed from November 2, 2022 to November 17, 2022.

In November 2022, the Company and the lender agreed to the fifth modification of the Note. The first payment due was delayed from November 17, 2022 to December 17, 2022. The lender received 12,698 additional warrants having a fair value of \$37,955, which were recorded as an additional debt discount and amortized over the remaining life of the Note.

In December 2022, the Company and the lender agreed to the sixth modification of the Note. The first payment due was delayed from December 17, 2022 to January 17, 2023. The lender received 12,698 additional warrants having a fair value of \$33,936, which were recorded as an additional debt discount and amortized over the remaining life of the Note.

In the first quarter 2023, the Company and the lender agreed to the seventh through eleventh modifications of the Note. The maturity was reset to May 16, 2023; the default and optional redemption rates were reset to 137.5% and the qualified offering, as described, was reset to \$3 million. The Company paid \$36,600 of accrued interest as part of these amendments.

In the second quarter 2023, the Company and the lender agreed to the twelfth modification of the Note. The maturity was reset to July 2, 2023; the default and optional redemption rates were reset to 142.5% and the qualified offering, as described, was reset to \$3 million in one continuous offering of a single security.

In the third quarter 2023, the Company and the lender agreed to the 13th modification of the Note. In exchange for the right to convert to common stock at 1.5 times the original principal balance should there be an event of default, the lender agreed to a five month extension of the maturity of this Note to December 2, 2023, and accrual of the monthly interest from July 2, 2023, to be paid at maturity.

In the fourth quarter 2023, the Company and the lender agreed to the 14th and 15th modifications of the Note. In exchange for receipt of \$5,000 of accrued interest for each modification, the maturity date was extended to January 31, 2024. Subsequent to December 31, 2023, certain terms of the note were amended for the 16th time was extended the note to April 2, 2024.

In January 2024, The Company and the lender agreed to the 16th modification of the Note. In exchange for receipt of \$15,000 of accrued interest and 30,476 additional warrants, having a fair value of \$114,285, which were recorded as an additional debt discount and amortized over the remaining life of the Note, for the modification, the maturity date was extended to April 2, 2024. This

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 7 - SENIOR SECURED NOTE PAYABLE, continued

modification allowed for a further extension to May 2, 2024, at the option of the Company in exchange for payment of \$10,000 of accrued interest and an additional 7,619 warrants. On March 25, 2024, the Company exercised the option to extend this note to May 2, 2024, the warrants had a fair value of \$28,571, which were recorded as an additional debt discount and amortized over the remaining life of the Note.

In April 2024, the Company and the lender agreed to the seventeenth modification of the Note. The maturity was reset to June 2, 2024, in exchange for the receipt of \$7,500 of accrued interest.

In May 2024, the Company and the lender agreed to the eighteenth modification of the Note. The maturity was reset to July 15, 2024, in exchange for the receipt of \$7,500 of accrued interest.

In July 2024, the Company and the lender agreed to the nineteenth modification of the Note. The maturity was reset to August 15, 2024, in exchange for the receipt of \$11,905 of accrued interest. This modification allowed for a further extension to September 15, 2024, at the option of the Company in exchange for payment of \$11,905 of accrued interest, which CUBT exercised.

In September 2024, the Company and the lender agreed to the twentieth modification of the Note. The maturity was reset to October 15, 2024, in exchange for the receipt of \$17,143 of accrued interest. This modification allowed for a further extension to November 15, 2024, at the option of the Company in exchange for payment of \$17,143 of accrued interest, which CUBT exercised.

In November 2024, the Company and the lender agreed to the twenty-first modification of the Note. The maturity was reset to November 15, 2025, in exchange for the receipt of \$17,143 interest, paid monthly.

In November 2025 the lender agreed to the 22nd amendment of this note, which extends the maturity to June 15, 2026, in exchange for the receipt of \$17,143 interest, paid monthly.

All penalties and interest were recorded as interest expense with penalties of \$1,237,368 and accrued interest of \$544,403 at December 31, 2025. Amortization of the discounts was zero in 2025 and 2024, respectively.

NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY

In March 2026, the Company completed a 1 for 150 shares reverse split of the common stock and a reduction of the authorized shares from 1.5 billion to 400 million, with no change to the par value. Accordingly all references to number of shares herein have been restated to reflect this reverse split.

At December 31, 2025 and 2024, the Company has 400,000,000 shares of par value \$0.0001 common stock authorized and 7,151,941 and 6,128,608 issued and outstanding, respectively. At December 31, 2025 and 2024, the Company has 200,000,000 shares of \$0.0001 par value preferred stock authorized with 826,000 and 647,500 Series A and 1,000,000 and 1,000,000 Series B and 24,000,000 and 24,000,000 Series C issued and outstanding, respectively.

Preferred Stock

The preferred shares have the following respective rights and privileges:

Series A Preferred - In May 2024, the Company amended the rights and privileges of the Series A. The amended rights and privileges are: Convertible into shares of common stock at the holder's option at a conversion price of \$0.0025 per share based on the purchase price of the preferred shares; are redeemable at the Company's option at the greater of price of 125% of the purchase price paid for the shares or the calculation of the book value per share of the Company made by an independent audit firm; carry 1 vote for each share of common stock that each Series A shares are convertible into common stock. There are no dividend rights and a stated liquidation value of \$1.00 per share of outstanding shares, with a preference over other corporate stock. The Series A shares may be subject to mandatory conversion based on a fundamental change, as defined in the Amended Articles of Incorporation.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued

Series B Preferred are convertible in common shares of common stock at the holder's option at a conversion price of \$0.0075 per share based on the purchase price of the preferred shares; are redeemable at the Company's option at a price of 125% of the purchase price paid for the shares; carry one vote for each common share that the Series B is convertible into at the record date; are senior to all other securities in the event of a liquidation. There are no dividend rights and a stated liquidation value of \$1.00 per share of outstanding shares, with a preference over other corporate stock. The Series B shares may be subject to mandatory conversion based on a fundamental change, as defined in the Amended Articles of Incorporation.

Series C Preferred are convertible into common stock at the holder's option aggregating 30% of the total issued and outstanding common shares at conversion date post conversion; carry one vote for each common share that the Series C is convertible into at the record date. There are no dividend rights and have liquidation rights commensurate with the underlying common stock each share of Series C is convertible into. The Series C shares may be subject to mandatory conversion based on a fundamental change, as defined in the Amended Articles of Incorporation.

In the fourth quarter 2025, the Company issued 45,000 shares of Series A preferred stock for \$45,000 in cash.

In the third quarter 2025, the Company issued 50,000 shares of Series A preferred stock for \$50,000 in cash. In the third quarter 2025, a holder converted 25,000 shares of Series A into 66,667 shares of common stock.

In the first quarter 2025, the Company issued 108,500 shares of Series A preferred stock for \$108,500 in cash.

In December 2024, the Company issued 132,500 shares of Series A preferred stock in exchange for \$132,500 in cash

In June 2024, the Company issued 515,000 shares of Series A preferred stock in exchange for \$505,000 in cash and a subscription agreement for \$10,000, which was received in July 2024.

In February 2024, the Company issued 252,750 shares of Series B preferred stock in exchange for \$252,750 in cash.

During the fourth quarter 2023, the Company issued 176,500 shares of Series B preferred stock in exchange for \$61,500 in cash and \$115,000 subscription receivable.

During the third quarter 2023, the Company issued 210,000 shares of Series B preferred stock in exchange for \$210,000 in cash.

During the first quarter 2023, the Company issued 163,750 shares of Series B preferred stock in exchange for \$163,750 in cash.

A deemed dividend for the Series C preferred stock is calculated and recorded as shares of common stock are issued. This is calculated as the increase in common shares that the Series C would receive upon conversion, as a result of the change in the number of common shares issued and outstanding during the period multiplied by the closing price of the common stock at the end of the period. The deemed dividend was \$91,200 and \$1,860,440 for the years ended December 31, 2024 and 2023, respectively.

Common Stock

In the third quarter 2025, the Company issued 333,333 shares of common stock with 333,333 warrants with an exercise price of \$4.50 per share and 333,333 warrants with an exercise price of \$7.50 per share, both with a 36 month maturity in exchange for \$150,000 in cash. In the third quarter 2025, a holder converted 25,000 shares of Series A into 66,667 shares of common stock.

In the second quarter 2025, the Company issued 11,111 shares of common stock with 11,111 warrants with an exercise price of \$4.50 per share and 11,111 warrants with an exercise price of \$7.50 per share, both with a 36 month maturity in exchange for \$5,000 in cash.

In the first quarter 2025, the Company issued 612,222 shares of common stock with 612,222 warrants with an exercise price of \$4.50 per share and 612,330 warrants with an exercise price of \$7.50 per share, both with a 36 month maturity in exchange for \$275,500 in cash.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued

During the third quarter 2024, the Company issued 106,667 shares of common stock under a consulting contract. The shares were valued at \$2.00 per share, which was the closing market price of the shares the day before the obligation arose, or \$212,800, and vested immediately.

During the fourth quarter 2023, the Company increased its authorized common shares to 1,500,000,000. During the fourth quarter 2023, the Company issued 233,333 shares of common stock valued at \$343,000 to an officer of the company as an inducement to enter into a new 24 month employment agreement. The value of these shares were amortized to expense over their six month vesting period. Also, the Company issued 100,000 shares of common stock valued at \$147,000 to a now former officer and director of the Company as an inducement to resign from the Board of Directors. These shares carry a 24 month non-compete clause. The value of these shares will be amortized over the life of the non-compete clause. In addition the Company issued 16,667 shares of common stock valued at \$24,500 to a now former director of the Company as an inducement to resign from the Board of Directors. These shares carry a 24 month non-compete clause. The value of these shares were amortized over the life of the non-compete clause. The total value of these 350,000 shares was \$514,500 of which \$314,416 and \$128,675 was amortized to expense in 2024 and 2023, respectively with \$71,409 remaining in prepaid expense at December 31, 2024. During the fourth quarter 2023, the Company issued 1,333,333 shares of common stock valued at \$2,080,000 to two current and one former officer of the company as settlement of \$1,411,333 accrued and unpaid salary. The Company recognized a loss on debt extinguishment of \$668,667 on this settlement. During the fourth quarter 2023, the Company issued 2,000 shares of common stock valued at \$10,200 to a consultant to settle the accumulated liability to issue common shares. During the fourth quarter 2023, investors exercised 143,603 warrants for cash of \$107,078 and a subscription receivable of \$625 under an inducement offer which reduced the exercise price from \$13.50, \$16.50 and \$22.50 per share to \$0.75 per share. Upon exercise the Company issued 143,603 common shares and 143,603 replacement warrants with an exercise price of \$1.50. Since the value of the inducement is considered an offering cost under ASU 2021-04 the value of the inducement offer including the replacement warrants was limited to the \$107,078 cash proceeds and did not have an impact on the financial statements as the fair value of the modified and replacement warrants would be considered equity issuance cost which would be credited and charged to additional paid in capital resulting in no net effect.

NOTE 10 - WARRANTS

In March 2026, the Company completed a 1 for 150 shares reverse split of the common stock and a reduction of the authorized shares from 1.5 billion to 400 million, with no change to the par value. Accordingly all references to number of warrants and their corresponding exercise price herein have been restated to reflect this reverse split.

| | 2025 | 2024 |
|--------------------------|-----------|-----------|
| Beginning balance | 434,873 | 500,852 |
| Issued | 1,976,000 | 38,095 |
| Exercised | - | - |
| Expired/Cancelled | | (104,074) |
| Ending Balance | 2,410,873 | 434,873 |

Warrants outstanding at December 31, 2025:

| Number | Remaining Life | Exercise Price |
|------------------|--------------------------------------|--------------------------------|
| 27,778 | 78 months | \$4.50 |
| 16,667 | 78 months | \$7.50 |
| 119,111 | 54 months | \$4.50 |
| 119,111 | 54 months | \$7.50 |
| 7,619 | 39 months | \$0.015 |
| 30,476 | 37 months | \$0.015 |
| 10,000 | 35 months | \$1.80 |
| 10,000 | 34 months | \$1.2825 |
| 10,000 | 33 months | \$1.8675 |
| 10,000 | 32 months | \$2.0025 |
| 111,111 | 32 months | \$4.50 |
| 111,111 | 32 months | \$7.50 |
| 222,222 | 31 months | \$4.50 |
| 222,222 | 31 months | \$7.50 |
| 10,000 | 31 months | \$2.07 |
| 10,000 | 30 months | \$2.5875 |
| 10,000 | 29 months | \$2.475 |
| 10,000 | 28 months | \$2.745 |
| 11,111 | 28 months | \$4.50 |
| 11,111 | 28 months | \$7.50 |
| 100,000 | 27 months | \$2.9475 |
| 370,000 | 27 months | \$4.50 |
| 370,000 | 27 months | \$7.50 |
| 42,222 | 26 months | \$4.50 |
| 42,222 | 26 months | \$7.50 |
| 50,795 | 24 to 19 months | \$0.015 |
| 152,381 | 14 months | \$0.015 |
| 143,603 | 11 months | \$3.00 |
| 23,333 | 5 months | \$16.50 |
| 26,667 | 5 months | \$15.00 |
| 2,410,873 | 29.76 months weighted average | \$5.16 weighted average |

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 10 - WARRANTS, continued

The aggregate intrinsic value of vested share warrants (the market value was less the exercise price) at December 31, 2025 was \$459,619.

During the third quarter 2025, the Company issued 333,333 common stock units which included two 333,333 warrants per unit. Both warrants carry a maturity of 36 months and one warrant has a \$4.50 exercise price and the second warrant carries a \$7.50 exercise price. During the third quarter the Company issued 177,778 warrants with an exercise price of \$4.50 and 177,778 warrants with an exercise price of \$7.50 as debt discount. 58,667 and 58,667 of these warrants were cancelled settlement of the debt.

During the second quarter 2025, the Company issued 11,111 common stock units which included two 11,111 warrants per unit. Both warrants carry a maturity of 36 months and one warrant has a \$4.50 exercise price and the second warrant carries a \$7.50 exercise price.

In April 2025 pursuant to a consulting contract, the Company issued warrants for services as follows: April 1 – 100,000 warrants with an exercise price of \$2.9475 with a three year maturity valued at \$195,338; May 1 – 10,000 warrants with an exercise price of \$2.745 with a three year maturity valued at \$18,207; June 1 – 10,000 warrants with an exercise price of \$2.475 with a three year maturity valued at \$16,415; July 1 - 10,000 warrants with an exercise price of \$2.5875 with a three year maturity valued at \$17,167; August 1 - 10,000 warrants with an exercise price of \$2.07 with a three year maturity valued at \$13,73; September 1 - 10,000 warrants with an exercise price of \$2.0025 with a three year maturity valued at \$13,294; October 1 - 10,000 warrants with an exercise price of \$1.8675 with a three year maturity valued at \$12,415; November 1 - 10,000 warrants with an exercise price of \$1.2825 with a three year maturity valued at \$8,527 and December 1 - 10,000 warrants with an exercise price of \$1.80 with a three year maturity valued at \$11,974. For the remaining three months of this contract, through March 1, 2026, the Company is required to issue 10,000 warrants on the first of each month with an exercise price set at 150% of the closing price of the common stock the day prior. The Company will record an expense for the fair value of these warrants calculated using the Black-Scholes model.

In June 2025 the Company issued two sets of 177,778 warrants as inducement for a short-term convertible note payable of \$74,000. Both warrants carry a maturity of 60 months and one warrant has a \$4.50 exercise price and the second warrant carries a \$7.50 exercise price. These warrants were valued at a total of \$74,000 and were recorded as a debt discount which is being amortized over the 90 day initial term of the note. In June 2025, the Company issued 27,778 warrants with a maturity of 84 months and an exercise price of \$4.50 and 16,667 warrants with a maturity of 84 months and an exercise price of \$7.50 as part of a settlement agreement with a vendor on an account payable. These warrants were valued at \$59,333 which reduced the amount of the gain realized on the settlement.

During the first quarter 2025, the Company issued 612,222 common stock units which included 2 warrants per unit. Both warrants carry a maturity of 36 months with an \$4.50 exercise price and a \$7.50 exercise price.

During the first quarter 2024, the Company and the lender agreed to a modification of the Note maturity, which included an option to further extend the maturity. In exchange for ultimately a three month extension of the maturity date, the lender received 30,476 and 7,619 additional warrants having a fair value of \$114,285 and \$28,572, respectively, which was recorded as an additional debt discount and amortized over the remaining life of the Note, and were fully amortized at December 31, 2024.

At December 31, 2025 and 2024, there were 2,410,873 and 434,873 warrants fully vested issued and outstanding with a weighted average exercise price of \$5.16 and \$2.82 per share. During 2025 and 2024, zero and 104,074 warrants expired, respectively. The method utilized to value the warrants granted was the Black-Scholes pricing model with the following assumption ranges: Expected life - three or five years; stock price between \$2.69 and \$4.65; volatility between 288% and 313.0%; exercise price between \$3.00 and \$0.015 and bond equivalent yield rate between 1.62% and 5.05%.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 10 - WARRANTS, continued

These warrants were valued using the Black-Scholes model with the following assumptions:

| | |
|----------------|-------------------|
| Expected life | 36 to 84 months |
| Stock price | \$1.34 to \$19.65 |
| Exercise price | \$2.48 to \$7.50 |
| Volatility | 320.79% to 619% |
| Dividend | \$0.00 |
| Discount rate | 3.69% to 4.02% |

NOTE 11 - NON-EQUITY INCENTIVE PLAN OPTIONS

In March 2026, the Company completed a 1 for 150 shares reverse split of the common stock and a reduction of the authorized shares from 1.5 billion to 400 million, with no change to the par value. Accordingly all references to number of options and their respective exercise price herein have been restated to reflect this reverse split.

During the fourth quarter 2023, the Company issued 366,667 options to three (one new) members of the Board of Directors. These options carry an exercise price of \$0.015 per share and expire in October 2033. These options were valued at \$539,000 and vest at the rate of 25% per quarter beginning January 2nd, 2024. The method utilized to value the options was the Black-Scholes pricing model with the following assumption ranges: Expected life - 6.5 years using the simplified method; stock price \$1.47 volatility 311.4%; exercise price \$0.015 and discount rate 2.52%. In 2024, \$449,169 of compensation expense was recognized. At December 31, 2025, the weighted average exercise price is \$0.015 and the weighted average life is 7.83 years.

NOTE 12 - EQUITY INCENTIVE PLAN

In March 2026, the Company completed a 1 for 150 shares reverse split of the common stock and a reduction of the authorized shares from 1.5 billion to 400 million, with no change to the par value. Accordingly all references to number of options and their respective exercise price herein have been restated to reflect this reverse split.

On August 26, 2021, the Company adopted an equity incentive plan providing for the issuance of shares of common stock, options or SARs with a rolling maximum number equal to 10% of the issued and outstanding Common Shares set at the beginning of each fiscal year. The Company may grant incentives to its directors, officers, employees and service providers. The options are exercisable for a maximum of up to ten years from the date of grant and may be subject to vesting provisions as set by the Plan Administrator.

As of December 31, 2025, there were 49,710 issued and outstanding equity incentive plan options which are all fully vested with a weighted average exercise price of \$7.77 per option and 15 months remaining life. At December 31, 2025, the closing market price of the stock was \$0.81 per share.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 12 - EQUITY INCENTIVE PLAN, continued

A summary of the Company's equity incentive plan options and changes during the year ended December 31, 2024 is as follows:

| | <u>Number of Options</u> | <u>Weighted average exercise price</u> |
|---------------------------|--------------------------|--|
| Balance January 1, 2024 | 49,710 | 7.77 |
| Granted | - | - |
| Exercised | - | - |
| Cancelled | - | - |
| Balance December 31, 2024 | <u>49,710</u> | <u>7.77</u> |
| No activity | - | |
| Balance December 31, 2025 | <u><u>49,710</u></u> | <u><u>\$ 7.77</u></u> |

The aggregate intrinsic value of vested share options (the market value was less the exercise price) at December 31, 2025 and 2024 was zero.

NOTE 13 - FINANCIAL INSTRUMENTS

(a) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its obligations associated with financial liabilities. The Company relies on cash flows generated from operations, as well as injections of capital through the issuance of the Company's capital stock to settle its liabilities when they become due.

(b) Interest Rate Risk The Company is not exposed to significant interest rate risk due to the short-term maturity of its monetary current assets and current liabilities.

NOTE 14 - GENERAL AND ADMINISTRATIVE EXPENSES

| | <u>Year ended December 31,</u> | |
|---|--------------------------------|----------------------------|
| | <u>2025</u> | <u>2024</u> |
| Compensation | \$ 391,625 | \$ 655,182 |
| Share based compensation | 349,944 | 976,386 |
| Professional fees | 460,820 | 347,119 |
| Other | <u>205,260</u> | <u>271,031</u> |
| Total general and administrative expenses | <u><u>\$ 1,407,649</u></u> | <u><u>\$ 2,249,718</u></u> |

NOTE 15 - INCOME TAXES

The Company recognizes deferred tax assets and liabilities for the tax effects of differences between the financial statements and tax basis of assets and liabilities. A valuation allowance is established to reduce the deferred tax assets if it is more likely than not that a deferred tax asset will not be realized.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 15 - INCOME TAXES, continued

The components of income tax provision (benefit) related to continuing operations are as follows at December 31:

| | <u>2025</u> | <u>2024</u> |
|----------------------|-------------|-------------|
| Current | \$ - | \$ - |
| Deferred | \$ - | \$ - |
| Total tax provisions | <u>\$ -</u> | <u>\$ -</u> |

The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31:

| | <u>2025</u> | <u>2024</u> |
|--|-----------------|-----------------|
| U.S. Federal statutory income tax rate | 21.0% | 21.0% |
| State income tax, net of federal benefit | 4.35% | 4.35% |
| Subtotal | <u>25.35%</u> | <u>25.35%</u> |
| Valuation allowance | <u>(25.35%)</u> | <u>(25.35%)</u> |
| | <u>0.0%</u> | <u>0.0%</u> |

The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31:

| | <u>2025</u> | <u>2024</u> |
|-----------------------------------|--------------------|--------------------|
| Deferred tax assets: | | |
| Net operating loss carry forwards | \$ 4,488,909 | \$ 3,901,771 |
| Stock based compensation | 2,451,897 | 2,204,432 |
| Other | <u>773,036</u> | <u>733,411</u> |
| Total | 7,713,842 | 6,839,614 |
| Deferred tax liabilities: | - | - |
| Less: valuation allowance | <u>(7,713,842)</u> | <u>(6,839,614)</u> |
| Net deferred tax assets | <u>\$ -</u> | <u>\$ -</u> |

The change in valuation allowance was (\$870,810) and (\$897,394) for the years ended December 31, 2024 and 2023, respectively. We have recorded a 100% valuation allowance related to the deferred tax asset for the income from operations. \$0.85 million of the Company's Net Operating Loss (NOL) carryforward may be subject to the IRS rules limiting the use of such carryforward due to the change in control of the Company in 2019. The remaining \$6.9 million of the current NOL and resulting income tax credits totals may be carried forward indefinitely.

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2025 and 2024, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

Curative Biotechnology, Inc
Notes to Financial Statements

NOTE 16 - COMMITMENTS AND CONTINGENCIES

The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company's financial position or results of operations.

NOTE 17 - CONCENTRATIONS OF CREDIT RISK

(a) Cash The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company had zero cash balance in excess of FDIC insured limits at December 31, 2025 and 2024.

NOTE 18 - SUBSEQUENT EVENTS

(a) Related party short term notes In February 2026, the maturity was extended to December 31, 2026.

(b) Deficiency in Stockholders Equity In the first quarter of 2026, the Company issued 600,000 common stock units which included 600,000 warrants with an exercise price of \$0.015 per share with a 36 month life in exchange for \$225,000 in cash.

(c) Warrants – In April 2025 pursuant to a consulting contract, the Company issued warrants for services in the first quarter 2026, as follows: January 1 –10,000 warrants with an exercise price of \$1.215 with a three year maturity valued at \$6,659; February 1 – 10,000 warrants with an exercise price of \$1.395 with a three year maturity valued at \$6,663 and March 1 – 10,000 warrants with an exercise price of \$1.095 with a three year maturity valued at \$6,662. The Company will record an expense for the fair value of these warrants calculated using the Black-Scholes model with the following assumption ranges: Expected life - three years; stock price between \$1.65 and \$1.97; volatility between 323% and 329%; exercise price between \$0.0165 and \$0.0197 and bond equivalent yield rate between 3.69% and 3.87%.

In the first quarter of 2026, the Company issued 600,000 common stock units which included 600,000 warrants with an exercise price of \$0.015 per share with a 36 month life in exchange for \$225,000 in cash.

In the first quarter 2026, the Company agreed to exchange 315,095 warrants that had been issued to a single investor/consultant in 17 combined issuances for a replacement warrant for 315,095 shares with a 36 month maturity and an exercise price of \$0.015. As a result the Company will record a loss of \$39,298.

In the first quarter 2026, the Company agreed to settle a \$99,000 accrued liability by issuance of a warrant for 333,333 shares with a 36 month maturity and an exercise price of \$0.015. As a result the Company will record a loss of \$265,853.